Recent News - Cannabis


Ullman Speaks with NutraIngredients-USA
August 26, 2020 | Cannabis | Health Services
Marc Ullman was quoted in a NutraIngredients-USA article, “AHPA event aims to guide CBD industry.” The article discusses how products containing cannabidiol (CBD) represent a rapidly growing yet uncertain market segment, with those in the industry often finding themselves with more questions than answers. Click here to read the full article. …
Read More
Share this article:
Ullman Quoted in NutraIngredients USA
August 21, 2020 | Cannabis | Health Services
Marc Ullman was quoted in a NutraIngredients USA article, “Upcoming event aims to help fill regulatory holes in hemp/CBD industry.” The article discusses how CBD firms are often unprepared for the regulatory compliance side of operating a dietary supplement firm. The upcoming event that is being discussed in the article looks to assist with that. …
Read More
Share this article:
Ullman to Present at Virtual Hemp-CBD Supplement Congress
July 20, 2020 | Cannabis | Health Services | Compliance Investigations & White Collar
On August 27, Marc Ullman will be presenting at the American Herbal Products Association (AHPA) Hemp-CBD Supplement Virtual Congress. The seminar will provide companies with an understanding of federal and state legal and regulatory obligations and current issues and opportunities in the hemp-CBD market. Click here to register. …
Read More
Share this article:
Ullman Cited in Article on CBD in Foods and Beverages
June 15, 2020 | Cannabis | Health Services
Marc Ullman was cited in Nutritional Outlook’s article, “High anxiety: Will CBD ever be legal in foods and beverages?” The article discusses whether or not the FDA will ever approve the use of CBD in foods and beverages. Currently, it is not a lawful ingredient. Ullman provided advice on the procedures necessary to prove the …
Read More
Share this article:
Ullman Lends Perspective on FDA Warning Letter
June 4, 2020 | Compliance Investigations & White Collar | Cannabis
Marc Ullman was quoted in a Nutraingredients-USA.com article entitled “Warning letter cites CBD’s regulatory status as leading issue.” The Food and Drug Administration sent a warning letter to a supplement manufacturer regarding various failures in good manufacturing practice (GMP). For the first time, however, the letter cited the health claims made about CBD as the first …
Read More
Share this article:
Shapiro Speaks to NYSBA Food, Drug and Cosmetic Law Section
January 29, 2020 | Cannabis | Compliance Investigations & White Collar
On Thursday, January 30, 2020, Steven Shapiro will present to the New York State Bar Association’s Food, Drug and Cosmetic Law Section as part of its Off-Label Promotion Update. His presentation is entitled “Promotion of CBD following Epidiolex for Rx, OTC drugs and other products. For information and to register, click here. …
Read More
Share this article:
Ullman’s Op-Ed on CBD Appears in Long Island Business News
January 29, 2020 | Cannabis | Compliance Investigations & White Collar
On January 29, 2020, Marc Ullman’s opinion piece, “FDA’s lack of CBD guidance is a disservice to Long Island firms,” appeared in Long Island Business News. Marc notes that an exploding market for CBD products has created a conundrum for companies wishing to cash in. Either they obey FDA’s regulations and lose out, or they break …
Read More
Share this article:
Ullman Quoted on Proposed CBD Legislation
January 21, 2020 | Cannabis | Compliance Investigations & White Collar
Marc Ullman spoke to Nutraingredients-USA about a new bill that would include CBD in the definition of dietary supplements in the federal Food, Drug and Cosmetic Act. The legislation is an attempt to cope with the raft of products now on the market that are technically illegal. Marc said he thinks the bill will only …
Read More
Share this article:
Ullman Quoted on FDA’s Targeting of CBD
January 17, 2020 | Cannabis | Compliance Investigations & White Collar
Marc Ullman was quoted in a Nutraingredients-USA story entitled “Warning letter analysis shows FDA has target on CBD, not hemp.” To read the article, click here. …
Read More
Share this article:
Ullman Quoted in Natural Products Insider
December 5, 2019 | Compliance Investigations & White Collar | Cannabis | Health Services
Marc Ullman was quoted in a Natural Products Insider article, “CBD industry hit with nearly half a dozen class action lawsuits.” The FDA’s batch of warning letters last month to CBD marketers spawned a growing number of proposed class action lawsuits. Click here to read the article. …
Read More
Share this article:
Next Page

Get legal updates and news delivered to your inbox